Abstract
The organic arsenical known as melarsoprol (Mel-B) is used to treat African trypanosomiasis. Recently, another arsenical, As2O3 was shown to be effective in treatment of acute promyelocytic leukaemia. We have investigated the anti-tumour activities of Mel-B either with or without all-trans-retinoic acid (ATRA) using the MCF-7 human breast cancer cells, as well as the PC-3 and DU 145 human prostate cancer cells both in vitro and in vivo. The antiproliferative effects of Mel-B and/or ATRA against breast and prostate cancer were tested in vitro using clonogenic assays and in vivo in triple immunodeficient mice. Furthermore, the mechanism of action of these compounds was studied by examining the cell cycle, levels of bcl-2, apoptosis and antiproliferative potency using a pulse-exposure assay. Clonogenic assays showed that the cancer cell lines were sensitive to the inhibitory effect of Mel-B (effective dose that inhibited 50% clonal growth [ED50]: 7 × 10–9 M for MCF-7, 2 × 10–7 M for PC-3, 3 × 10–7 M for DU145 cells. Remarkably, the combination of Mel-B and ATRA had an enhanced antiproliferative activity against all three cancer cell lines. Furthermore, the combination of Mel-B and ATRA induced a high level of apoptosis in all three cell lines. Treatment of PC-3 and MCF-7 tumours growing in triple immunodeficient mice with Mel-B and ATRA either alone or in combination markedly retarded tumour size and weight of the tumours without major side-effects. In conclusion, our results suggest that either Mel-B alone or with ATRA may be a useful, novel therapy for breast and prostate cancers. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Apted FIC (1970) Treatment of human trypanosomiasis. In: The African Trypanosomiases, Mulligan HW (ed), pp. 684–710. George Allen & Unwin: London
Bollag W and Holdener EE (1992) Retinoids in cancer prevention and therapy. Ann Oncol 3: 513–526
Bollag W and Peck R (1994) Cancer chemotherapy by combination of retinoids with cytokines and vitamin D analogs. Experimental and clinical results. Ann Oncol 5: 17–22
Borsellino N, Belldegrun A and Bonavida B (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55: 4633–4639
Campbell MJ (1998 a) Expression of RARβ sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride D3 analog. Endocrinology 139: 1972–1980
Campbell MJ, Dawson M and Koeffler HP (1998 b) Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide. Br J Cancer 77: 739–744
Cavigelli M (1996) The tumour promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269–6279
Chen GQ (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML protein. Blood 88: 1052–1061
Chen GQ (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3exerts dose-dependent dual effects on APL cells. Blood 89: 3345–3353
Chen W (1998) Tumour promoter arsenic activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Sch. Mol Cell Biol 18: 5178–5188
de Vos S (1996) Effects of retinoid X receptor (RXR)-class selective ligands on proliferation of prostate cancer cells. Prostate 32: 115–121
Dong JT and Luo XM (1994) Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 315: 11–15
Donofrio PD (1987) Acute arsenic intoxication presenting as Guillain–Barré-like syndrome. Muscle Nerve 10: 1114–1120
Douer D and Koeffler HP (1981) Retinoic acid: inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 69: 277–283
Elstner E (1996) Synergistic decrease of clonal proliferation, induction of differentiation and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3analogs and 9-cis retinoic acid. J Clin Invest 99: 349–360
Evans RM (1988) The steroid and thyroid receptor superfamily. Science 240: 889–895
Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539–542
Friedheim EAH (1949) The active form of tryparsamide TPB in the treatment of human trypanosomiasis. Am J Trop Med 29: 173–180
Gianni M (1998) Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91: 4300–4310
Gudas LJ (1992) Retinoids, retinoid-responsive genes, cell-differentiation, and cancer. Cell Growth Diff 4: 655–662
Harris JR, Morrow M and Norton L (1997). In: Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S and Rosenberg ST (eds), pp. 1557–1617. Lippincott-Raven: Philadelphia
Huang ME (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–572
Israel K, Sanders BG and Kline K (1995) RRR-alpha-tocopherol succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutrition Cancer 24: 161–169
Jaafar R (1993) Skin cancer caused by chronic arsenical poisoning – a report of three cases. Med J Malaysia 48: 86–92
König A (1997) Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 90: 562–570
Li X and Darzynkiewicz Z (1995) Labeling DNA strand breaks with BrdUTR. Detection of apoptosis and cell proliferation. Cell Prolif 28: 571–579
Mangelsdorf DJ, Umesono K and Evans RM (1994) The retinoid receptors. In: The Retinoids, Sporn MB, Roberts AB and Goodman DS (eds), pp. 319–349. Raven Press: New York
Mervis J (1996) Ancient remedy performs new tricks [news]. Science 273: 578
Milord F (1992) Efficacy and toxicity of eflornithine for the treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340: 652–655
Miyashita T and Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151–157
Munker R, Norman AW and Koeffler HP (1986) Vitamin D compounds: effects on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 87: 424–430
Petkovich M (1992) Regulation of gene expression by vitamin A: the role of nuclear retinoic acid receptors. Annu Rev Nutr 12: 443–471
Pienta KJ, Nguyen NY and Lehr JE (1993) Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 53: 224–226
Shi Y, Glynn JM and Guilgert LJ (1992) Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257: 212–214
Snow ET (1992) Metal carcinogenesis: mechanistic implications. Pharmacol Ther 53: 31–65
Soignet SL, Maslak P and Wang Z-G (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med 339: 1341–1348
Sun HD, Ma L and Hu XC (1992) Arsenic trioxide treated 32 cases of acute promyelocytic leukemia. Chin. J Integrat Chin West Med 12: 170–171
Symonds H (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703–711
Teelmann K (1993) Comparison of the therapeutic effects of a new arytenoid, Ro 40-8757, and all-trans - and 13-cis-retinoic acids on rat breast cancer. Cancer Res 53: 2319–2325
Thompson CB (1994) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456–1462
van Nieuwenhove S (1992) Advances in sleeping sickness therapy. Am Soc Belge Med Trop 72: 39–51
Warrell RP Jr (1993) Acute promyelocytic leukemia. N Engl J Med 329: 177–189
Yonish-Rouach E (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347
Yunmbam MK and Roberts JF (1993) In vivo evaluation of reuterin and its combinations with suramin, melarsoprol, DL-a-difluoromethyl-ornithine and bleomycin in mice infected with Trypanosoma brucei. Comp Biochem Physiol 105: : 521–524
Zhang P, Wang SY and Hu XC (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17: 58–60
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Koshiuka, K., Elstner, E., Williamson, E. et al. Novel therapeutic approach: organic arsenical (melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo . Br J Cancer 82, 452–458 (2000). https://doi.org/10.1054/bjoc.1999.0942
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0942
Keywords
This article is cited by
-
Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines
Molecular Biology Reports (2011)
-
Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145
Journal of Experimental & Clinical Cancer Research (2008)